Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUVENAL E MARTINEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1558459529
CMS profile
69926
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,279.40

50 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,279.40 50

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUVENAL E MARTINEZ

NPI 1558459529 · CMS profile ID 69926

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

50 matching records · $1,279.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 50 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 50.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $20.0012/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898727915 CMS
IDORSIA PHARMACEUTICALS US INC $19.1712/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942812543 CMS
Lilly USA, LLC $12.3611/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918135567 CMS
Biohaven Pharmaceutical Holding Company Ltd. $22.9011/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664641 CMS
Abbott Laboratories $63.7911/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920495857 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.0911/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887444011 CMS
Lilly USA, LLC $14.1210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918105053 CMS
Bayer HealthCare Pharmaceuticals Inc. $121.6010/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930057541 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.5010/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930028289 CMS
Biohaven Pharmaceutical Holding Company Ltd. $23.3209/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664639 CMS
AstraZeneca Pharmaceuticals LP $114.2409/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915869645 CMS
AstraZeneca Pharmaceuticals LP $16.8409/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914743973 CMS
Novo Nordisk Inc $124.9909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898628097 CMS
Novartis Pharmaceuticals Corporation $16.6609/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893942157 CMS
AstraZeneca Pharmaceuticals LP $15.0409/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915515423 CMS
Biohaven Pharmaceutical Holding Company Ltd. $24.9508/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664637 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5608/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959504753 CMS
Lilly USA, LLC $14.0708/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918152583 CMS
Lilly USA, LLC $13.2407/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918097235 CMS
Lilly USA, LLC $17.8907/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918097233 CMS
Biohaven Pharmaceutical Holding Company Ltd. $23.6507/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664635 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5607/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959625521 CMS
SANOFI-AVENTIS U.S. LLC $27.3306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740525 CMS
PFIZER INC. $20.4506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949178931 CMS
Lilly USA, LLC $13.7406/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918110481 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5606/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959710971 CMS
AstraZeneca Pharmaceuticals LP $5.2105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915517196 CMS
AstraZeneca Pharmaceuticals LP $15.5605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915070975 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.9805/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930180815 CMS
Biohaven Pharmaceutical Holding Company Ltd. $24.3505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664633 CMS
Janssen Pharmaceuticals, Inc $13.8804/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885966799 CMS
SANOFI-AVENTIS U.S. LLC $23.2704/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740505 CMS
AstraZeneca Pharmaceuticals LP $14.8904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915068117 CMS
GlaxoSmithKline, LLC. $20.0604/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944933813 CMS
PFIZER INC. $19.6004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949110593 CMS
Lilly USA, LLC $13.2404/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918105055 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.1604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887444009 CMS
Novo Nordisk Inc $18.4604/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898628087 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.7304/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959537979 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.2903/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929942289 CMS
SANOFI-AVENTIS U.S. LLC $21.9503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740487 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.5802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929955963 CMS
ABBVIE INC. $20.6902/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107343 CMS
AstraZeneca Pharmaceuticals LP $16.2002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915671683 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.0202/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959618983 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.0002/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664631 CMS
Kowa Pharmaceuticals America, Inc. $16.4701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900359821 CMS
SANOFI-AVENTIS U.S. LLC $20.3601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740463 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.6101/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664629 CMS
Amarin Pharma Inc. $23.2201/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913957435 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,824.81 72
PY2020 $1,108.16 66
PY2021 $1,714.64 78
PY2022 $1,279.40 50
PY2023 $1,687.36 46
PY2024 $1,313.52 50
PY2025 $665.19 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,400.63 16
PY2025 Principal investigator $701,734.65 46
PY2024 Principal investigator $1,015,383.57 140
PY2023 Principal investigator $1,037,707.93 416
PY2022 Principal investigator $88,070.01 24
PY2021 Principal investigator $334,298.45 64
PY2020 Principal investigator $148,277.65 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

416 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,064.00 12/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032827
Principal investigator 1 Amgen Inc. $5,511.52 12/11/2023 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
P3 AD Extension No dispute reported 06/30/2026 1029654397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,878.00 12/01/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032474
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 11/03/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26,028.00 10/20/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,533.60 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,270.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,878.00 10/13/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997032835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,235.00 10/02/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030904
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $82,147.50 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,661.10 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,535.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,912.00 09/25/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997031735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50,247.00 08/04/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138,049.70 07/17/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030799
Principal investigator 1 Amgen Inc. $7,676.76 07/12/2023 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
P3 AD Vaccine Study No dispute reported 06/30/2026 1029655241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35,512.20 06/26/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,527.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,747.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68,553.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,437.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $27,329.40 06/02/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $118.00 05/12/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $164.00 05/12/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030726
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $47.25 04/11/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $330.00 04/11/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $330.00 04/11/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997030015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/05/2023 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997029997